ArticleJournal of thoracic disease2017

Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation.

Eun Hye Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.